Loading company…
Ocelot Bio develops treatments for liver diseases, including the clinical-stage therapeutic peptide OCE-205.
Ocelot Bio is a clinical-stage biopharmaceutical company developing treatments for patients with liver diseases. Its lead product, OCE-205, targets complications of portal hypertension and is in a phase 2 trial for HRS-AKI. Based in San Diego, it raised USD 36 million in a Series A round in March 2022.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in